Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.32 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SGK1 | O00141 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833747 | 0.85 | HTR6 (0.39) | KMT2AMEN1CA1CA2 | |
| SCHEMBL4828764 | 0.81 | SGK1 (0.41) | KMT2AMEN1PPARGCA1CA2 | |
| SCHEMBL4833307 | 0.81 | PKM (0.38) | PKMALDH1A1GAAMAPTHTT | |
| SCHEMBL4834229 | 0.81 | CA1 (0.44) | KMT2AMEN1CA1CA2ALDH1A1 | |
| SCHEMBL4834410 | 0.81 | CA1 (0.47) | KMT2AMEN1CA1CA2PKM | |
| SCHEMBL4834365 | 0.80 | LMNA (0.37) | KMT2AMEN1CA1CA2MAPT | |
| SCHEMBL4836622 | 0.80 | MEN1 (0.42) | KMT2AMEN1GPR27CA1CA2 | |
| SCHEMBL4831181 | 0.79 | ALPL (0.45) | KMT2APKMGAAMAPT | |
| SCHEMBL4834114 | 0.79 | ALDH1A1 (0.46) | KMT2AMEN1PKMALDH1A1GAA | |
| SCHEMBL4827037 | 0.79 | MAPT (0.43) | KMT2AMEN1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | claimed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | KMT2A 324/4885MEN1 303/4885HSD11B1 3465/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | KMT2A 334/4885MEN1 1454/4885HSD11B1 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.